nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO
|
Kollmannsberger, C. |
|
|
16 |
8 |
p. 1326-1333 |
artikel |
2 |
Adjuvant chemotherapy for elderly patients (≥70 years) with early high-risk breast cancer: a retrospective analysis of 260 patients † † Presented in part at the 40th Annual Meeting of the American Society of Clinical Oncology, poster session, June 5–8, 2004, New Orleans, US.
|
Brunello, A. |
|
|
16 |
8 |
p. 1276-1282 |
artikel |
3 |
A 2-month cisplatin–epirubicin–paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: a phase II study
|
Frasci, G. |
|
|
16 |
8 |
p. 1268-1275 |
artikel |
4 |
Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology
|
Krüger, W.H. |
|
|
16 |
8 |
p. 1381-1390 |
artikel |
5 |
Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene
|
Menendez, J.A. |
|
|
16 |
8 |
p. 1253-1267 |
artikel |
6 |
Chemotherapy-induced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients
|
Vanhuyse, M. |
|
|
16 |
8 |
p. 1283-1288 |
artikel |
7 |
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors
|
Holden, S.N. |
|
|
16 |
8 |
p. 1391-1397 |
artikel |
8 |
Clinical impact of whole-body FDG-PET for evaluation of response and therapeutic decision-making of primary lymphoma of bone
|
Park, Y.H. |
|
|
16 |
8 |
p. 1401-1402 |
artikel |
9 |
Cyclophosphamide-methotrexate ‘metronomic’ chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation
|
Bocci, G. |
|
|
16 |
8 |
p. 1243-1252 |
artikel |
10 |
High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study
|
Josting, A. |
|
|
16 |
8 |
p. 1359-1365 |
artikel |
11 |
In this issue
|
|
|
|
16 |
8 |
p. 1215 |
artikel |
12 |
Is cardiac troponin T serum level an accurate surrogate for acute doxorubicin-related myocardial injury?
|
Ferretti, G. |
|
|
16 |
8 |
p. 1403-1404 |
artikel |
13 |
Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?
|
Bajetta, E. |
|
|
16 |
8 |
p. 1374-1380 |
artikel |
14 |
Little response to zoledronic acid in a child of juvenile myelomonocytic leukemia (JMML) harboring the PTPN11 mutation
|
Shimada, H. |
|
|
16 |
8 |
p. 1400 |
artikel |
15 |
Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature
|
Hennessy, B.T. |
|
|
16 |
8 |
p. 1289-1296 |
artikel |
16 |
Metachronous gastric MALT lymphoma and early gastric cancer: is residual lymphoma a risk factor for the development of gastric carcinoma?
|
Copie-Bergman, C. |
|
|
16 |
8 |
p. 1232-1236 |
artikel |
17 |
Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer
|
Negri, F.V. |
|
|
16 |
8 |
p. 1305-1310 |
artikel |
18 |
Myeloma bone disease: pathophysiology and management
|
Terpos, E. |
|
|
16 |
8 |
p. 1223-1231 |
artikel |
19 |
Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer
|
Gradishar, W.J. |
|
|
16 |
8 |
p. 1297-1304 |
artikel |
20 |
Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates
|
Folprecht, G. |
|
|
16 |
8 |
p. 1311-1319 |
artikel |
21 |
Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus
|
Mauer, A.M. |
|
|
16 |
8 |
p. 1320-1325 |
artikel |
22 |
Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia
|
Chen, C.-C. |
|
|
16 |
8 |
p. 1366-1373 |
artikel |
23 |
Reply to the Letter to the Editor on “Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients”, by I. Cohen Ann Oncol 2005; 16: 1399
|
Paridaens, R. |
|
|
16 |
8 |
p. 1402-1403 |
artikel |
24 |
Response to “Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients”, by L. Morales et al. (Ann Oncol 2005; 16: 70–74)
|
Cohen, I. |
|
|
16 |
8 |
p. 1402 |
artikel |
25 |
Secondary leukemia after epirubicin-based adjuvant chemotherapy in operable breast cancer patients: 16 years experience of the French Adjuvant Study Group
|
Campone, M. |
|
|
16 |
8 |
p. 1343-1351 |
artikel |
26 |
Sentinel node biopsy is reliable in early-stage cervical cancer but not in locally advanced disease
|
Barranger, E. |
|
|
16 |
8 |
p. 1237-1242 |
artikel |
27 |
Severe interstitial pneumonitis following rituximab and bleomycin-containing combination chemotherapy
|
Ghesquieres, H. |
|
|
16 |
8 |
p. 1399 |
artikel |
28 |
Table of Contents
|
|
|
|
16 |
8 |
p. i-ii |
artikel |
29 |
The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer
|
Zhang, X.-T. |
|
|
16 |
8 |
p. 1334-1342 |
artikel |
30 |
Treatment of advanced breast cancer: the good, the bad and the ugly
|
Colleoni, M. |
|
|
16 |
8 |
p. 1219-1221 |
artikel |
31 |
Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas
|
Monfardini, S. |
|
|
16 |
8 |
p. 1352-1358 |
artikel |
32 |
What is the impact of sentinel node biopsy in the management of cancer?
|
Lejeune, F.J. |
|
|
16 |
8 |
p. 1217-1218 |
artikel |